WO2024201420 - MIRNA-484 INHIBITORS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/201420
Publication Date
03.10.2024
International Application No.
PCT/IB2024/053115
International Filing Date
29.03.2024
Title **
[English]
MIRNA-484 INHIBITORS AND USES THEREOF
[French]
INHIBITEURS DE MIARN-484 ET LEURS UTILISATIONS
Applicants **
BIORCHESTRA CO., LTD.
SK BIOPHARMACEUTICALS CO., LTD.
Inventors
RYU, Jin-Hyeob
JANG, Ha Na
LIM, Jongyeob
JUNG, Yeon-Joo
PARK, Young Jin
KIM, Insun
LIM, Yu Na
KANG, Howon
JOUNG, Chanmi
CHOI, Eunju
PARK, Ah Hyung
YOOK, Chaehyun
CHO, Seokhwan
SHIN, Yujin
GIL, So-Young
Priority Data
63/493,526
31.03.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3523 | |
| EPO | Filing, Examination, Granting | 29375 | |
| Japan | Filing, Examination, Granting | 3291 | |
| South Korea | Filing, Examination, Granting | 3197 | |
| USA | Filing, Examination, Granting | 13940 |
Total:
53,326
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure includes the use of a miR-484 inhibitor for treating a disease or disorder associated with the increased level of miR-484. In some aspects, the miR-484 inhibitor is capable of reducing the expression of a gene and/or protein associated with miR-484.[French]
La présente invention comprend l'utilisation d'un inhibiteur de miR-484 pour traiter une maladie ou un trouble associé au niveau accru de miR-484. Selon certains aspects, l'inhibiteur de miR-484 est capable de réduire l'expression d'un gène et/ou d'une protéine associés à miR-484.